9月27日,CDE官网显示,银诺医药苏帕鲁肽(Supaglutide)上市申请获药监局受理。据推测,本次申报适应症为苏帕鲁肽单药治疗在饮食和运动干预后血糖控制不佳的2型糖尿病患者以及联合治疗二甲双胍治疗后血糖控制不佳的2型糖尿病患者。 点击下载:12份报告!读懂GLP-1/GLP-1R(免费下载) 苏帕鲁肽是一款人源化长效GLP-1受体...
爱企查为您提供苏帕鲁肽supaglutide2023年企业商标信息查询,包括企业商标注册信息、商标logo,商标类别等企业商标信息查询,让您更轻松的了解苏帕鲁肽supaglutide商标信息,查询更多关于苏帕鲁肽supaglutide商标信息就到爱企查官网!
2023年9月27日,CDE官网显示,银诺医药苏帕鲁肽(Supaglutide)上市申请获药监局受理。据推测,本次申报适应症为苏帕鲁肽 单药治疗在饮食和运动干预后血糖控制不佳的2型糖尿病患者以及 联合治疗二甲双胍治疗后血糖控制不佳的2型糖尿病患者。苏帕鲁肽是一款人源化长效GLP-1受体激动剂,正在2型糖尿病、肥胖和NASH等代谢病...
详细解释: 苏帕鲁肽是银诺医药首个管线产品,并已获得2型糖尿病适应症三期临床研究24周双盲期疗效终点。研究结果表明,苏帕鲁肽可以有效降低在饮食和运动干预后血糖控制不佳的2型糖尿病患者的血糖。“苏帕鲁肽是一个glp-1与免疫球蛋白的fc片段融合形成的融合蛋白,它克服了glp-1分子量小、半衰期短的特点,在体内形成一...
Supaglutide (supa), a novel GLP-1RA, is in late-stage clinical investigation for T2D. The efficacy and safety are being investigated in 340 patients with T2D inadequately controlled on metformin in this randomized, double-blind, placebo-controlled phase 3 clinical trial (NCT04998032). Supa 3 ...
7月25日,CDE官网显示,银诺医药苏帕鲁肽(Supaglutide)获批临床,用于治疗肥胖症。 点击下载GLP-1系列专题:多肽药物研发演变 苏帕鲁肽是一款人源化长效GLP-1受体激动剂,正在2型糖尿病,肥胖和NASH等代谢病领域开展积极的研发布局。苏帕鲁肽能促进胰岛素的分泌,促进胰岛β细胞再生,提升胰岛β细胞质量,是具有标本兼治潜力的...
Supaglutide, a novel GLP-1-IgG Fc fusion protein, exerts hypoglycemic effects in type 2 diabetic db/db mice and spontaneous diabetic monkeys. In this study, we investigated the pharmacokinetics and pharmacodynamics of supaglutide by single or repeated subcutaneous and intravenous injection (s) in...
SupaglutideMetabolic dysfunction-associated steatohepatitisLiver biopsyLiver fat contentGlucagon-like peptide 1 (GLP-1) is an incretin hormone and plays an important role in regulating glucose homeostasis. GLP-1 has a short half-life due to degrading enzyme dipeptidyl peptidase-IV and rapid kidney ...
Notably, during the intervention course supaglutide significantly reduced body-weight gain in these obese diabetic mice, associated with reduced fat mass (but not the lean mass), improved lipid profile, i.e., declined serum triglyceride, and free fatty acid levels compared to the placebo control...
Supaglutide (Supa) is a weekly dosing GLP-1 analog. We conducted a randomized, double-blind, placebo-controlled, multiple dose-escalation study to investigate the safety, PK/PD and efficacy of Supa in patients with T2D. 40 subjects were randomized in a 4:1 ratio to receive Supa (sc., ...